1. Home
  2. PRZO vs ENSC Comparison

PRZO vs ENSC Comparison

Compare PRZO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.90

Market Cap

25.1M

Sector

N/A

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.10

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
ENSC
Founded
2014
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
6.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
PRZO
ENSC
Price
$0.90
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
513.3K
418.0K
Earning Date
08-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,007,440.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.42
1.51
52 Week Low
$0.53
$1.08
52 Week High
$3.16
$9.88

Technical Indicators

Market Signals
Indicator
PRZO
ENSC
Relative Strength Index (RSI) 25.41 27.48
Support Level $1.13 $1.08
Resistance Level $1.20 $1.24
Average True Range (ATR) 0.06 0.13
MACD -0.03 -0.01
Stochastic Oscillator 5.39 1.75

Price Performance

Historical Comparison
PRZO
ENSC

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: